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Background: In 2014, breast cancer remains a major cause of mortality worldwide mostly due to tumor relapse
and metastasis. There is currently a great interest in identifying cancer biomarkers and signalling pathways
mechanistically related to breast cancer progression. Matrix metalloproteinase-9 (MMP-9) is a member of matrix
degrading enzymes involved in cancer development, invasion and metastasis. Our objective was to investigate
MMP-9 expression in normal human breast tissue and to compare it to that of breast cancer of various histological
grades and molecular subtypes. We also sought to correlate MMP-9 expression with the incidence of metastasis,
survival rates and relapse in breast cancer patients.
Methods: MMP-9 was first studied using in silico analysis on available DNA microarray and RNA sequencing data of
human breast cancer tissues and human breast cancer cell lines. We next ascertained MMP-9 expression in both
normal breast tissue and in human breast carcinoma tissue microarrays.
Results: Significant increase in MMP-9 expression was found in breast cancer cells where compared to normal
breast tissue. A positive correlation could also be established between elevated levels of MMP-9 and breast cancer
of high histological grade. Furthermore, our results indicate that not only MMP-9 is differentially expressed between
each molecular subset but also, more importantly MMP-9 overexpression revealed itself as a startling feature of
triple-negative and HER2-positive breast cancers. Lastly, the clinical relevance of MMP-9 overexpression is strongly
supported by its significant association with a higher incidence of metastasis and relapse.
Conclusions: Differential expression of MMP-9 reflects the extent of cellular differentiation in breast cancer cells
and is closely related to the most aggressive subtypes of breast cancer. Hence, MMP-9 is a promising prognostic
biomarker of high-grade breast cancer. In our opinion, MMP-9 expression could help segregate subsets of aggressive
breast cancer into clinically meaningful subtypes.
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Breast cancer is the most common malignancy and the
second leading cause of cancer-related death after lung
cancer among women in the United States and Europe
[1]. Due to major advances in screening and early diag-
nostic procedures, most breast cancer patients are diag-
nosed at an early stage. However, 6% to 10% of patients
still present with metastatic breast cancer at the time of
diagnosis; for those patients, relapses tend to occur* Correspondence: louis.gaboury@umontreal.ca
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unless otherwise stated.earlier and survival rates are shortened [2]. Cancer me-
tastasis is considered to develop in a step-wise fashion
leading to the acquisition of new capabilities by tumor
cells helping them to thrive and evade natural barriers
[3]. Cancer cells detach themselves from the primary
tumor, migrate and invade surrounding tissues, enter the
vasculature, circulate throughout the body and eventu-
ally reach secondary sites where they extravasate, and
populate distant organs [4].
Degradation of the extracellular matrix (ECM) is
thought to be a crucial step in the formation of tumor
metastasis. Multiple proteolytic enzymes such as plasmin,
cathepsins, and matrix metalloproteinases (MMPs) are
known to degrade ECM [5]. Matrix metalloproteinase-9Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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the gelatinase subfamily of MMPs. It is excreted as an
inactive pro-enzyme that undergoes activation upon
cleavage by different types of extracellular proteases [6].
MMP-9 activity is thought to be regulated by different
biochemical stimulators such as growth factors and cyto-
kines whose expression appear to modulate intracellular
signaling pathways [7]. MMP-9 has the ability to degrade
denaturated collagens which have been first cleaved by
various collagenases such as MMP-1, MMP-8 and MMP-
13 [8,9]. In addition, MMP-9 degrades type IV collagen
which is the main component of the basement membrane
[10]. It exerts different roles in the dissemination process
such as tumor invasion, tumor-induced angiogenesis, and
immunomodulation of the tumor microenvironment. In
addition, MMP-9 is instrumental in creating so-called pre-
metastatic niches that foster colonization of distant organs
[11]. Elevated tissue levels of MMP-9 are also associated
with invasion, metastasis and poor prognosis in different
types of cancer including cervical [12], colorectal [13],
ovarian [14] and breast cancer [15]. Furthermore elevated
levels of MMP-9 in the serum and urine have also been
found to be associated with metastasis and poor prognosis
in a diversity of cancers [16].
Our goal was to assess the potential clinical usefulness
of MMP-9 as a prognostic biomarker of breast cancer.
To achieve that aim, we first studied MMP-9 mRNA ex-
pression using in silico analysis on available DNA micro-
array and RNA sequencing data of human breast cancer
tissues and breast cancer cell lines. We next evaluated
MMP-9 expression at the protein level using immunohis-
tochemical analyses on tissue microarrays containing both
normal and neoplastic breast tissues. Our data were next
correlated with patients’ outcome specifically looking at
the incidence of metastases, relapse and overall survival.
Our results indicate that MMP-9 is not only differentially
expressed in different molecular breast cancer subtypes
but also overexpressed in triple-negative and HER2-
positive breast cancers. Overexpression of MMP-9 tightly
correlates with a higher incidence of metastasis and re-
lapse. Taken together, our data indicate that differential
expression of MMP-9 reflects the degree of differentiation
of breast cancer cells and that its overexpression tightly
correlates with the most aggressive subtypes of breast can-
cers. Hence, MMP-9 is a potentially useful biomarker of
aggressive and metastatic subtypes of breast cancer.
Methods
In silico analysis
The web application bc-GenExMiner [17] was used for
correlation analysis of MMP-9 gene expression on a
dataset comprising over 3,063 microarrays. However,
only 1210 patients could be correctly assigned precisely
to each molecular subtype. The “aov” and “TukeyHSD”functions were carried out to compare the mRNA levels
within each breast cancer molecular subtypes. The
ANOVA was applied to check for an overall difference
of expression levels between each molecular subtypes.
The Tukey multiple comparisons of means were used to
test for a significant difference between two subtypes (e.g.
Luminal A vs. Basal). For both tests, a p-value < 0.05 was
considered significant. The mRNA level of MMP-9 in 51
breast cancer cell lines were also studied using publically
available microarrays and mRNA sequencing breast can-
cer cell line datasets [18].
Patients and tissue samples
A retrospective study was carried out using a cohort of
300 female breast cancer patients comprising tumors of
different histological grades. Archived Formalin-fixed,
paraffin-embedded (FFPE) samples containing tumor tis-
sues were collected for the study. Tumor grades were
confirmed using the Modified Scarff-Bloom-Richardson-
Elston-Ellis grading system (SBR-EE) [19]. A complete set
of follow-up data including the onset of metastasis and re-
lapse were acquired. We also obtained 19 normal breast
tissues from healthy women undergoing plastic surgery to
serve as internal controls. Benign breast conditions such
as mammary fibroadenoma and myofibroblastoma were
included as negative controls [20]. In addition, a number
of extraneous tissues such as colon, thyroid and placenta
were included in each TMA. All samples were obtained
from Centre Hospitalier de l’Université de Montréal
(CHUM) after granting the approval of the research ethical
committee (Comité d'éthique de la recherche du CHUM
CENTRE DE RECHERCHE, Approval No. SL 05.019).
Tissue microarray (TMA)
Sections (4 μm) from each paraffin block were stained
with hematoxylin and eosin (H&E) and examined by two
independent pathologists. Core punches, 1 mm in diam-
eter, were drilled from representative areas contained
within each FFPE tumor blocks. Each core was realigned
in duplicate or triplicate into recipient blocks according
to the intended design of the map using a Manual Tis-
sue Arrayer I (Beecher Instruments). Blocks were next
inverted and incubated overnight in the oven over a
glass slide. TMA blocks were allowed to cool until they
could easily detach from the glass slide. Tissue sections
from each TMA were prepared and one slide from each
block was stained with H&E to review the diagnoses and
histological grades on all tissue samples. Additional rep-
resentative sections from each block were submitted to
automated immunohistochemical (IHC) staining.
Immunohistochemistry
Immunohistochemical assays were performed on FFPE
tissues obtained from each TMAs. These assays were
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on an automated immunostainer (Discovery XT system,
Ventana Medical Systems, Tucson, AZ). Immunohisto-
chemical analysis of MMP-9 (polyclonal; ab38898,
dilution 1/100, no pretreatment, Abcam, Canada) was
carried out to detect both the pro- and the active form
of MMP-9 [21]. In addition, immunohistochemical ana-
lysis of estrogen receptor (ER; monoclonal, clone SP1,
RTU, sCC1, Ventana Medical Systems), progestrone re-
ceptor (PR; monoclonal, clone 1E2, RTU, sCC1, Ventana
Medical Systems), HER2 (monoclonal, clone 4B5, RTU,
sCC1, Ventana Medical Systems), Ki-67 (monoclonal,
clone SP6, dilution 1/100, pretreated sCC1, BioCare
medical) were used as surrogate markers of breast can-
cer molecular subtypes [22]. Antigen retrieval was per-
formed with proprietary reagents followed by incubation
with the primary antibody. Sections were then incubated
with a specific secondary biotinylated antibody for 32
minutes. Streptavidin horseradish peroxidase, and 3,3-
diaminobenzidine were used according to the manu-
facturer’s instructions (DABmap detection kit, Ventana
Medical Systems). Sections were next counterstained with
Gill’s hematoxylin and sodium bicarbonate. Finally, each
slide was scanned at high resolution (40X) using the
Nanozoomer Digital Pathology equipment (Hamamatsu,
Bridgewater, NJ). Two independent pathologists reviewed
all stained sections on two separate occasions.
Estrogen receptor (ER) and progesterone receptor (PR)
status were scored using Allred’s method. In brief, the
sum of the proportion and average intensity scores of
positive tumor cells were calculated and results dis-
played on a scale ranging from 0 to 8. The cutoff point
used to differentiate between positive and negative sam-
ples were as follows: tumors with Allred scores ≥ 3 (cor-
responding to as few as 1% to 10% weakly positive cells)
were considered to be positive. Those tumors that had
Allred score of less than 3 were considered to be nega-
tive. HER2 overexpression was carried out according to
the College of American Pathologists (CAP)-approved
scoring system as follows: no immunostaining or mem-
brane staining which is incomplete or barely perceptible
within ≤ 10% of the invasive tumor cells → 0; incomplete
membrane or barely perceptible staining within >10% of
invasive tumor cells → 1+; circumferential membrane
staining that is incomplete and/or weak/moderate
within >10% of the invasive tumor cells or complete
membranous staining that is intense within ≤ 10% of the
invasive tumor cells → 2+ and circumferential membran-
ous staining that is complete and intense→ 3+ [20]. Scor-
ing of MMP-9 and Ki-67 expression on each core was
carried out using a two tier scoring system. The first par-
ameter corresponds to the percentage of immunoreactive
cells also known as the quantity score (QS). QS was esti-
mated as follows (no staining was scored as 0, 1-10% ofcells with positive staining were scored as 1, >10- 50% as
2, >50-70% as 3, and >70-100% as 4). We next assessed
the second parameter (staining intensity score), which was
rated as follows: No staining → 0, weak staining →1,
moderate staining → 2, and strong staining → 3. The
product of the quantity and the staining intensity scores
represents the total IHC score that ranges from 0 to 12
[23,24]. IHC scores of 0 to 4 were considered to represent
low levels of expression while score from >4 to 12 were
considered as high levels of expression.
IHC staining for ER, PR, HER2 and Ki-67 were used as
surrogate markers to classify breast cancer tumors into lu-
minal A, luminal B, HER-2 positive and triple negative
breast cancer. Luminal A was defined as being (ER posi-
tive, PR positive, HER-2 negative and Ki-67 < 14%), lu-
minal B was defined as being either (ER, PR, HER-2
positive) or (ER positive, PR positive, HER-2 negative and
Ki-67 ≥ 14%). Triple negative breast cancers consisted of
tumors that lack expression of ER, PR and HER-2. HER-2
positive tumors that failed to express either ER or PR were
considered to belong to the HER-2 positive subtype [22].
Statistical analyses
All statistical analyses were carried out using different
packages of the R language (http://www.R-project.org/).
The distribution of MMP-9 among different molecular
subtypes is depicted using bar charts. Non-parametric
tests were used due to the nature of ordinal and categor-
ical data. The overall relationship between MMP-9 scores
and molecular subtypes was evaluated using the chi-
square test. Correlation analysis for immunohistochemical
expression levels was carried out using the Spearman’s rho
correlation coefficient. Chi-square test was realized with
Yates’ continuity correction and a two-sided Fisher exact
test was performed to analyze metastasis. Kaplan-Meier
plot was drawn to show the overall survival for low-level
and high-level expression of MMP-9. Statistical signifi-
cance was considered, with a p-value less than 0.05. Uni-
variate and multivariate logistic regression were used to
identify the significant factors among histological grades,
histological subtypes, molecular subtypes, metastasis and
age that affect the level of MMP-9 expression. The results
were interpreted in terms of odds ratio (OR). Univariate
and multivariate Cox models were used in survival ana-
lysis and the results were interpreted in terms of relative
risk (RR). Statistical significance was determined by the
confidence interval (CI). Only CI that does not include 1
are considered significant.
Results
In silico analysis: MMP-9 is overexpressed in basal-like
and HER2-positive breast cancers
The web application bc-GenExMiner [17] was used to
compare the mRNA levels within each breast cancer
Figure 1 In silico analysis of MMP-9 mRNA expression in breast cancer subtypes. The heat map and table are produced from the bc-GenExMiner
database v3.0 showing the expression of MMP-9 at mRNA level in different molecular subtypes of breast cancer as determined by PAM50.
Overexpression of MMP-9 is associated with basal-like and HER2-positive breast cancers. The “aov” and “TukeyHSD” functions were carried out to
compare the mRNA levels within each breast cancer molecular subtypes.
Figure 2 Expression of MMP-9 mRNA in human breast cancer cell lines. In silico analysis showing elevated MMP-9 mRNA expression levels in
basal-like breast cancer cell lines (e.g. CAL85-1, HCC1395, HCC1143, DU4475, HCC1937, MDA-MB-231 and HCC38). Luminal breast cancer cell lines
with HER2 amplification also display stronger MMP-9 mRNA expression (AU565, UAA-893 and HCC2218). MCF7 and KPL1 cell lines are the only
luminal cell lines with mildly elevated MMP-9 mRNA expression. (B = basal, L = luminal, L + H = Luminal with HER2 amplification).
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rays. In brief, the gene expression data is given for those
patients that could be assigned to a certain molecular sub-
type (robust classifications for 1210 patients). In Figure 1,
the table indicates for each subtype the proportion of pa-
tients with low, intermediate, and high gene expression.
Gene expression values were being beforehand split in
order to form three equal groups. This means that “high
expression” is the 1/3 of the patients with highest expres-
sion of MMP-9 and “low expression” is the lower 1/3 of
the patients. As depicted in Figure 1, 57% of basal-like and
50% of HER2-positive breast cancer patients expressed
high levels of MMP-9. In comparison, only 12% of those
subtypes had a reduced expression of MMP-9. In sharp
contrast, only 16% of the luminal A breast cancer subtype
demonstrate increased expression of MMP-9. Data from
the luminal B subtype indicate that 36% of patients have
high levels of MMP-9 expression while approximately
30% maintained low levels of MMP-9. To expand on the
results obtained from the microarray datasets, we investi-
gated mRNA expression of MMP-9 in 51 breast cancer
cell lines of different molecular subtypes [25-27] using
publically available microarrays and mRNA sequencing
breast cancer cell line datasets [18]. As shown in Figure 2,
overexpression of MMP-9 was present in basal-like breast
cancer cell lines CAL85-1, HCC1395, HCC1143, DU4475,Figure 3 Validation of MMP-9 antibody specificity for IHC studies. (A)
cancer cells after incubating the section with MMP-9 primary antibody. (B)
non-immune serum that contains IgG (same isotype/ same species) showin
of breast tissue and (D) Benign breast fibroadenoma do not express MMP-HCC1937, MDA-MB-231 [28] and HCC38. Interestingly,
many luminal breast cancer cell lines known to have
HER2 gene amplification (AU565, UAA-893 and HCC2218)
also exhibited high levels of MMP-9 expression. Notably,
MCF7 and KPL1 cell lines were the only luminal cell lines
that revealed a modest increase in MMP-9 expression
above baseline levels [29].
MMP-9 expression is markedly decreased or absent in
normal human breast tissue
Optimization of MMP-9 immune reactivity was a pre-
requisite to validating the specificity of the IHC reaction.
In accordance with the Human Protein Atlas [30] and a
review of the literature, human colorectal carcinoma was
used as a positive control to assess the levels of MMP-9
expression in human cancers [31]. Our results are in
complete agreement with this prediction as shown by the
strong cytoplasmic labeling observed in colorectal carcin-
oma cells (Figure 3A). Additional adjacent sections from
the same colonic tumor incubated with a non-immune
serum containing IgG (same isotype/same species) re-
mained entirely negative. Of note, all subsequent steps of
the immunostaining reaction such as addition of the sec-
ondary antibody and the revealing reaction were carried
out in a strictly identical fashion (Figure 3B). We also
thought fit to include benign breast lesions such asHuman colorectal carcinoma with intense cytoplasmic labeling of the
Adjacent section from the same colorectal tumor incubated with a
g complete lack of expression of MMP-9. (C) Benign myofibroblastoma
9. Magnification 20X (A-D).
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as negative controls [20]. Again, no immune reactivity
could be detected after the successive addition of MMP-9
primary antibody, secondary antibody and chromogen.
Once all immunostaining conditions were satisfactorily
established, we carried out IHC reactions on TMAs
comprising both normal and neoplastic breast tissues.
Our results indicate that 74% of normal breast tissues
fail to express any MMP-9 reactivity in the luminal,
myoepithelial cells and stromal cells surrounding normal
breast ducts (Figure 4A). However, in a minority of nor-
mal breast tissues (26%) MMP-9 was faintly expressed
and restricted to the cytoplasm of luminal, myoepithelialFigure 4 Expression of MMP-9 in normal breast tissue.
(A) Normal breast lobule lacking MMP-9 expression in both luminal and
myoepithelial cells. Adjacent stromal cells also fail to express MMP-9
(74% of the patients). (B) Normal breast tissue exhibiting faint
expression of MMP-9 in the cytoplasm of luminal cells, myoepithelial cells
and in a few stromal cells surrounding normal breast acini. A & B are
two distinct normal breast tissue from the same TMA incubated with
anti-MMP9 antibody. Magnification 40X (A&B), 63X inset in Figure 4B.and a few adjacent stromal cells (Figure 4B). MMP-9 did
not label either the nucleus nor the cell membrane of
any of these cells. Notably, the level of MMP-9 expres-
sion in the luminal cells consistently exceeded that
present in the adjacent stromal cells.
Elevated levels of MMP-9 are present in carcinoma cells of
triple negative, HER2-positive tumors and nodal metastases
Next we aimed to validate the results obtained from the
in silico analysis on human breast tissue. We studied the
expression of MMP-9 at the protein level and assessed
the cellular and subcellular localization of MMP-9.
MMP-9 expression was evaluated in 300 human tumor
tissues representative of each molecular subtypes of breast
cancer whose definition was based on the use of the fol-
lowing surrogate markers: ER, PR, HER2 and Ki-67 [22].
As shown in Figure 5A, only 33.3% of luminal A (p = 0.05)
and 43.3% of luminal B (p < 0.01) expressed elevated levels
of MMP-9. In contrast, high levels of MMP-9 expression
were found in 87.9% of HER2-positive and 79.4% of triple-
negative breast cancer when compared to normal (p <
0.001). Low levels of MMP-9 expression were detected in
the cytoplasm of cancer cells in both luminal A and B
breast tumors. Indigenous stromal cells surrounding can-
cer cells in luminal A and B revealed only faint levels of
MMP-9 expression (Figure 5B and C). On the other hand,
elevated levels of MMP-9 expression were detected in the
stroma surrounding cancer cells in both triple-negative
and HER2-positive breast cancer. Nevertheless, the level
of MMP-9 in the cytoplasm of cancer cells always
exceeded that found in adjacent stromal cells (Figure 5D
and E). Furthermore, when MMP-9 levels were evaluated
in the cytoplasm of carcinoma cells present in 13 meta-
static lymph nodes, it was found that all tumor cells
(100%) displayed elevated levels of MMP-9 whereas the
surrounding lymphocytic and stromal cells failed to ex-
press MMP-9 (Figure 5F).
We next conducted univariate logistic-regression ana-
lysis on our data to sort out the role of a number of pa-
rameters such as histological grades, molecular subtypes
and metastasis on the level of MMP-9 expression. This
analysis confirmed the association between the high
levels of MMP-9 expression (total scores >4) with tu-
mors of high histological grade (Grade III) including
both HER2-positive and triple-negative breast cancers
(Table 1). Hence, we can safely conclude that MMP-9
protein expression in vivo strongly supports both in
silico analyses on microarray dataset as well as data
gathered from analysis of breast cancer cell lines.
Overexpression of MMP-9 is associated with a higher
incidence of metastases
We next investigated whether elevated levels of MMP-9
protein expression in carcinoma cells could predict the
Figure 5 Overexpression of MMP-9 is associated with triple-negative, HER2-positive breast tumors and nodal metastases. (A) Histogram
showing percentage of breast cancer patients in each molecular subtype category that express low and high level of MMP-9. Both HER2-positive
and triple-negative subtypes demonstrate elevated levels of MMP-9 that are significantly different from those observed in normal breast tissue.
The number of patients in each group was mentioned over each bar. The overall relationship between MMP-9 scores and molecular subtypes
was evaluated using the chi-square test. (B) Luminal A and (C) Luminal B subtypes showing low level of MMP-9 expression. (D) HER2-positive
and (E) Triple-negative subtypes displaying strong cytoplasmic labeling in cancer cells and surrounding stromal cells. (F) Metastatic lymph node
demonstrating elevated levels of MMP-9 expression in the cytoplasm of metastatic breast cancer cells. The surrounding lymphocytic and stromal
cells did not stain with anti-MMP-9 antibody. Magnification 20X (B-E), 5X (F), 40X inset in Figure 5F.
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rates. To that end, we reviewed the clinical charts of 200
patients for the period extending from 2000 to 2013.
Out of 200 Patients, 121 (60.5%) patients have high
MMP-9 expression and 79 (39.5%) pateints have low
MMP-9 expression. Increased levels of MMP-9 were
found to be associated with a higher incidence of metas-
tasis (Figure 6). The results were considered significant
when the percentage of patients who developed metasta-
ses significantly differed in terms of low and high levels
of MMP-9 expression. Only lymph node (p < 0.001),
lymphovascular invasion (p = 0.007) and lung metastasis
(p = 0.001) reached statistical significance when comparedto patients with low MMP-9 expression. Additional file 1
indicates the distribution of high and low MMP-9 expres-
sion in patients with and without metastases.
Univariate analysis of our data demonstrated the associ-
ation between elevated levels of MMP-9 expression and
the increased likelihood to develop metastasis (OR = 2.17,
95%CI = 1.48-3.23, p-value = 0.0001) (Table 1). Moreover,
to examine which clinical factors could affect the relation-
ship between MMP-9 and metastasis, multivariate logistic-
regression analysis was carried out. Triple-negative
molecular subtype proved to be the only statistically
independent predictor of metastasis (OR = 7.92, 95%CI =
2.90-21.6, p-value =0.0001) (Table 2). This suggests that
Table 1 Univariate analysis of different factors that could
affect level of MMP-9 expression
Parameters OR 95% CI p-value
Grades
Grade I Reference
Grade II 1.74 0.82-3.73 0.15
Grade III 2.61 1.36-5.08 < 0.001
Molecular subtypes
Luminal A Reference
Luminal B 0.51 0.26-0.99 0.05
HER2-positive 8.01 3.85-18.46 0.001
Triple-negative 3.90 2.48-6.19 0.001
Metastasis (No) Reference
Metastasis (Yes) 2.17 1.48-3.23 0.001
OR = odds ratio, CI = confidence interval.
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in predicting metastasis rather than any of the other bio-
logical factors examined.High levels of MMP-9 are associated with a shorter
latency to relapse and shorter survival after relapse (SAR)
Likewise, when we looked at the association between
MMP-9 and relapse, we found that enhanced expression
of MMP-9 was associated with a shorter latency to clin-
ical relapse: (Mean time for relapse = 3912 days, n = 121)
which is statistically significant (p = 0.014). This con-
trasts with the values observed in patients with low
MMP-9 levels of expression (Mean time for relapse =
4957 days, n = 79) (Figure 7A). However, using a multi-
variate analysis, histological grades, histological subtypes
and molecular subtypes were found to have no impact
on relapse in this patient’s population.Figure 6 Overexpression of MMP-9 is associated with a higher incide
higher incidence of metastasis. Only lymph node, lymphovascular invasion
compared to patients with low MMP-9 expression. Chi-square test was real
were performed to analyze metastases.Finally, the Kaplan-Meier overall survival (OS) curve
obtained from the same cohort of patients indicates that
increased expression levels of MMP-9 are associated
with a shorter OS (Mean OS = 6469 days, n = 16) when
compared to those tumors expressing low levels of
MMP-9 (Mean OS = 6984 days, n = 6). However, no sig-
nificant difference could be identified between OS for
patients having high or low levels of MMP-9 expression.
Interestingly, univariate analysis shows that patients with
higher levels of MMP-9 expression harbor a significant
high risk of death after relapse (RR = 3.05, p = 0.04)
(Figure 7B). It is also worth mentioning that we could
not find any statistically significant correlation between
the expression of MMP-9 in the tumor stroma and the
occurrence of metastasis or overall survival in the same
patients.
Discussion
In the present paper, we provide both indirect and direct
evidence that MMP-9 participates to breast cancer pro-
gression and impact on clinical outcome. There are
many studies reporting the association of elevated levels
of MMP-9 with a higher incidence of metastases and
poor clinical outcome. We found that high expression of
MMP-9 is specifically correlated with high-grade breast
cancers that include both triple-negative and HER-2
positive breast cancers.
Previous studies have provided conclusive evidence
that MMP-9 is involved in several key processes that
contribute to breast cancer development, progression,
invasion and metastasis [32-34]. Here we performed in
silico analysis of 1210 DNA microarrays of human breast
cancer tissues and RNA sequencing data of 51 human
breast cancer cell lines to assess MMP-9 mRNA expres-
sion. We found that MMP-9 mRNA expression in both
basal-like and HER2-positive tumors reached significantlynce of metastases. Increased expression of MMP-9 is associated with
and lung metastases reached the level of statistical significance when
ized with Yates’ continuity correction and a two-sided Fisher exact test
Figure 7 Overexpression of MMP-9 is associated with shorter
time to relapse and shorter survival after relapse. (A) High levels
of MMP-9 expression are associated with shorter time to relapse
(p = 0.014). (B) High levels of MMP-9 expression are associated with
shorter survival after relapse (p = 0.04).
Table 2 Multivariate analysis model of MMP-9 that include
metastasis, histological subtypes and molecular subtypes
Parameters OR 95% CI p value
Metastasis
Luminal A 0.97 0.45-2.07 0.93
Luminal B 3.52 0.81-15.27 0.12
HER2-positive 0.77 0.16-3.61 0.79
Triple-negative 7.92 2.90-21.61 0.001
OR = odds ratio, CI = confidence interval.
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egory. When the expression of MMP-9 in breast cancer
cell lines is considered, it is worth mentioning that cell
lines with a basal-like phenotype and those that overex-
pressed HER2 reached the highest levels of MMP-9 ex-
pression. In contrast, cell lines with luminal phenotype
failed to demonstrate elevated levels of MMP-9. This
strongly suggested to us that MMP-9 expression varied
according to cell differentiation and histological grades.
Hence, we decided to construct human breast cancer tis-
sue microarrays (TMA) comprising a wide selection of
tumors belonging to each category of breast cancer mo-
lecular subtypes. Those tumors were classified as triple-
negative, HER2-enriched, luminal A and luminal B based
on the expression profile of four surrogate markers (ER,
PR, HER2, Ki-67) [22]. We also included normal breast
tissue to serve as a basis for comparison. To thoroughly
validate the robustness of our IHC assay we first included
a number of internal and external controls. Whereas co-
lonic adenocarcinoma strongly expressed MMP-9, two be-
nign breast lesions (fibroadenoma and myofibroblastoma)
failed entirely to express MMP-9 under the same condi-
tions. Once the experimental procedures were set up, we
performed the IHC assay on TMAs. One important find-
ing was that normal breast tissue displayed either a
complete lack of positivity or barely perceptible labeling
with the antibody directed against MMP-9. This is con-
sistent with previous observation by others reporting only
a weak expression of MMP-9 in normal breast tissue
[35,36]. Indeed, low levels of MMP-9 expression in normal
breast tissue are expected since in most tissues MMP-9 is
an inducible and not a constitutively expressed gene [37].
Evidently, this sharply contrasts with the high levels of ex-
pression of MMP-9 found in the cytoplasm of both
HER2-positive and triple-negative breast cancers cells.
Hence, our findings support the conclusions of recently
published studies indicating a positive correlation between
high levels of MMP-9 expression and triple-negative
breast cancers [20,38,39]. Our results may also explain the
findings of La Rocca et al. who showed that high serum
levels of MMP-9 are present in HER2 amplified breast
cancers [40]. In this context, abnormally elevated levels of
MMP-9 can be envisaged as a response to local secretionof inflammatory cytokines and growth factors, such as
interleukin 1 (IL-1) and tumor necrosis alpha (TNFα),
which may lead to either activation of NF-kB, a well-
known inducer of MMP-9 production, or hypomethyla-
tion of its promoter [41]. One cautionary note should be
raised though, since high levels of MMP-9 do not neces-
sarily imply high MMP-9 activity as the protein is
produced as an inactive pro-enzyme. Moreover, active
MMP-9 can be completely neutralized by protease inhibi-
tors such as tissue inhibitors of metalloproteinases
(TIMPs) [42]. As for the production site of MMP-9 in
breast tumors, our results suggest that carcinoma cells are
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cell consistently exhibited a much weaker degree of
expression.
Finally, we wanted to correlate clinical outcome char-
acteristics such as onset of metastasis, survival rates and
tumor relapse with MMP-9 levels. Our results confirm
that overexpression of MMP-9 is tightly correlated with
lymphovascular invasion, regional node metastasis, a
shorter time to relapse and a reduced SAR. Taken to-
gether, our data underscore the role of MMP-9 in pro-
moting breast cancer metastases in lymph node and
lungs. This finding is consistent with both in vitro and
in vivo studies reporting high levels of MMP-9 expres-
sion in highly metastatic cell lines [43] and its contribu-
tion in metastatic progression [39]. Also, this supports
the finding of van ’t Veer et al. [44] who demonstrated
in a DNA microarray study that MMP-9 is significantly
upregulated in poor prognosis signature of breast cancer.
Although we have not directly addressed the question on
how MMP-9 fosters invasion and nodal metastasis, there
are numerous conceivable explanations that can be put
forth such as alteration of basal membrane components,
diminished cell-to-cell adhesion, release of ECM-bound
growth factors and chemotactic molecules, stimulation of
angiogenesis and induction of the epithelial-mesenchymal
transition (EMT) [45-49].
At any rate, our findings clearly emphasized the clin-
ical potential of MMP-9 as a prognostic biomarker in
breast cancer. This is in agreement with Wu et al. [50]
who suggested the potential role of MMP-9 as a bio-
marker for breast cancer progression. Interestingly, the
first fully commercialized and FDA approved microarray-
based multigene assay for breast cancer, MammaPrint®,
does include MMP-9 among its 50 panel genes [51,52].
Given on the one hand the overwhelming interest in de-
veloping prognostic and predictive breast cancer assays
and, on the other, the recognition that so called “wound-
healing” or “invasion” gene signatures are important to
predict tumor relapse and benefit to chemotherapy, one
might consider including MMP-9 alone or in combination
with other genes in the development of other multigene
multiplex assays.
Conclusion
In summary, our results indicate that overexpression of
MMP-9 is closely associated with breast cancers of high
histological grade including triple-negative and HER2-
positive molecular subtypes. Increased levels of expres-
sion of MMP-9 are also correlated with the onset of
nodal metastases, a reduced time interval to relapse and
a shorter SAR. Taken together, our findings suggest that
the differential expression of MMP-9 contributes to
breast cancer heterogeneity and is a key characteristic of
the “molecular signature” of subsets of breast cancer. Inour opinion, MMP-9 expression could help segregate
subsets of aggressive breast cancer into clinically mean-
ingful subtypes. Lastly, our results suggest that MMP-9
is a valuable gene/protein candidate to be considered in
the development of a multi-gene panel or multiplex
proteomic assay to predict clinical outcome.
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